1190 related articles for article (PubMed ID: 17875719)
1. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
2. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
Hoffmann D; Meyer B; Wildner O
J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
[TBL] [Abstract][Full Text] [Related]
3. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
4. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
5. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.
Shim SH; Lee CT; Hun Hah J; Lee JJ; Park SW; Heo DS; Sung MW
Cancer Sci; 2010 Feb; 101(2):482-7. PubMed ID: 19922505
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
7. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
Toivonen R; Suominen E; Grenman R; Savontaus M
Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
Bernt KM; Ni S; Tieu AT; Lieber A
Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
[TBL] [Abstract][Full Text] [Related]
9. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus.
Zhou W; Zhu H; Chen W; Hu X; Pang X; Zhang J; Huang X; Fang B; He C
Cancer Gene Ther; 2011 May; 18(5):336-45. PubMed ID: 21183948
[TBL] [Abstract][Full Text] [Related]
11. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
12. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
[TBL] [Abstract][Full Text] [Related]
13. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.
Sova P; Ren XW; Ni S; Bernt KM; Mi J; Kiviat N; Lieber A
Mol Ther; 2004 Apr; 9(4):496-509. PubMed ID: 15093180
[TBL] [Abstract][Full Text] [Related]
14. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins.
Hu B; Zhu H; Qiu S; Su Y; Ling W; Xiao W; Qi Y
Biochem Biophys Res Commun; 2004 Dec; 325(4):1153-62. PubMed ID: 15555548
[TBL] [Abstract][Full Text] [Related]
15. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
16. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
Hoffmann D; Wildner O
Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
[TBL] [Abstract][Full Text] [Related]
17. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
[TBL] [Abstract][Full Text] [Related]
18. Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses.
Schmitz M; Graf C; Gut T; Sirena D; Peter I; Dummer R; Greber UF; Hemmi S
Gene Ther; 2006 Jun; 13(11):893-905. PubMed ID: 16482201
[TBL] [Abstract][Full Text] [Related]
19. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
20. Assessment of CAR- or CD46-dependent adenoviral vector-mediated TRAIL gene therapy in clinical adenocarcinoma lung cancer cells.
Wang Y; Ma L; Wang S; Bao Y; Ni C; Guan N; Zhao J; Fan X
Oncology; 2009; 77(6):366-77. PubMed ID: 20068366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
